Table 2.

Oncological outcomes for vulvar SCC patients, by p16, p53 or ‘other’ immunohistochemistry status.

Characteristic	p16 (n = 45)	p53 (n = 36)	Others (n = 67)	P	Total
Duration of Follow-Up (months)	74 (43–111)	68 (27–104)	39 (12–68)	<0.01	58 (21–92)
Palliative intent	5 % (2)	3 % (1)	25 % (15)	0.01	13 % (18)
All-Cause Mortality	13 % (6)	47 % (17)	52 % (35)	<0.01	39 % (58)
Tumour-Specific Mortality	2 % (1)	31 % (11)	19 % (13)	<0.01	17 % (25)
Recurrence	15 % (6)	64 % (21)	43 % (26)	<0.01	40 % (53)